Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer

Clinical Cancer Research

Volumn 5, Issue 9, 1999, Pages 2338-2343

  Dowsett, M ^a   Pfister, C ^b   Johnston, S R D ^a   Miles, D W ^c   Houston, S J ^c   Verbeek, J A ^b   Gundacker, H ^b   Sioufi, A ^d   Smith, I E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c GUY S HOSPITAL   (United Kingdom)

^d NOVARTIS PHARMA K K   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTRONE; LETROZOLE; TAMOXIFEN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; FEMALE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 0032836573     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Dowsett, M., Jones, A., Jacobs, S., Trunet, P., and Smith, I. E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin. Cancer Res., 1: 1511-1515, 1995.
2. Iveson, T. J, Smith, I. E., Ahern, J., Smithers, D. A., and Dowsett, M. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with breast cancer. Cancer Res., 53: 266-270, 1993.
3. Dombernowsky, P., Smith, I., Falkson, G., et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol., 16: 453-461, 1998.
4. Gershanovich, M., Chaudri, H. A., Campos, D., et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann. Oncol., 9: 639-645, 1998.
5. Harvey, H., Lipton, A., Whittes, D. S., et al. Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer. Cancer Res., 42: 3451s-3453s, 1982.
6. Smith, I. E., Harris, A. L., Morgan, M., Gazet, J-C., and McKinna, J. A. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast cancer. Cancer Res., 42: 3430s-3433s, 1982.
7. Ingle, J. N., Green, S. J., Ahmann, D. L. et al Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J. Clin. Oncol., 4: 958-964, 1986.
8. Rose, C., Kumby, C., Mouridsen, H. T., et al. Combined endocrine treatment of postmenopausal patients with advanced breast cancer. A randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide and hydrocortizone. Breast Cancer Res. Treat., 7 (Suppl.): 45-50, 1986.
9. Lien, E. A., Anker, G., Lonning, P. E., Solheim, E., and Ueland, P. M. Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Res., 50: 5851-5857, 1990.
10. Van Ginkel, R., Janssens, B., Callens, M., Goeminne, N., Wouters, L., and De Coster, R. Effects of combined and sequential treatment with tamoxifen and the aromatase inhibitor vorozole on 7,12-dimethyibenz(a)anthracene-induced mammary carcinoma in the rat. Cancer Chemother. Pharmacol., 38: 21-28, 1996.
11. Lu, Q., Liu., Y., Long, B., and Brodie, A. Combined treatment with aromatase inhibitors and tamoxifen in a nude mice model. Proc. Am. Assoc. Cancer Res., 39: 384-385, 1998.
12. Ingle, J. N., Suman, V. J., Johnson, P. A., Krook, J. E., Mailliard, J. A., Wheeler, R. H., Loprinzi, C. L., Perez, E. A., Jordan, V. C., and Dowsett, M. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin. Cancer Res., 5: 1642-1649, 1999.
13. Marfit, F., Pineau, V., Siorifi, A., and Godbillin, J. High-performance liquid chemotography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection. J. Chromatogr. B., 683: 251-258, 1996.
14. Dowsett, M., Goss, P. E., Powles, T. J., Hutchinson, G., Brodie, A. M. H., Jeffcoate, S. L., and Coombes, R. C. Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer. Optimization of therapeutic dose and route. Cancer Res., 47: 1957-1961, 1987.
15. Trunet, P. F., Mueller, P. H., Girard, F., et al. The effects of fadrozole hydrodiloride on aldosterone secretion in healthy male subjects. J. Clin. Endocrinol. Metab., 74: 571-576, 1992.
16. Hayward, J. L., Carbone, P. P., Henson, J-C., Kumoaka, S., Segaloff, A., and Rubens, R. D. Assessment of response to therapy in advanced breast cancer. Eur. J. Cancer, 13: 89-94, 1977.
17. Sioufi, A., Gauducheau, N., Pineau, V., et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm. Drug Dispos., 18: 779-789, 1997.
18. Colussi, D. M., Parisot C. Y., and Lefèvre, G. Y. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J. Clin. Pharmacol., 38: 727-735, 1998.
19. Wirz, B., Valles, B., Parkinson, A., et al. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole. , 10: 359, 1996.
20. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. Identification of the cytochrome P450 IIIA family as the enzyme involved in the N-desmethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911-1919, 1991.
21. Daniels, L., Blankson, E. A., Henderson, C. J., Harris, A. H., Wolf, C. R., Lennard, M. S., and Tucker, G. T. Delineation of human cytochromes P450 involved in the metabolism of tamoxifen. Br. J. Clin. Pharmacol., 34: 153-154, 1992.
22. White, I. N. H., Davies, A., Smith, L. L., Dawson, S., and De Matteis, F. Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45: 21-30, 1993.
23. Nuwaysir, E. F., Dragan, Y. P., Jefcoate, C. R., Jordan, V. C., and Pilot, H. C. Effects of tamoxifen administration on the expression of xenobiotic metabolizing enzymes in rat liver. Cancer Res., 55: 1780-1786, 1995.
24. Jefferson, J. W. Tamoxifen-associated reduction in tricyclic antidepressant levels in blood. J. Clin. Psychopharmacol., 15: 223-224, 1995.
25. Sakai, F., Cheix, F., Clavel, M. et al. Increases in steroid binding globulins induced by tamoxifen in patients with carcinoma of the breast. J. Endocrinol., 76: 219-226, 1978.